Alto Neuroscience (NYSE:ANRO) Issues Earnings Results

Alto Neuroscience (NYSE:ANRO) announced its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09, Zacks reports.

Alto Neuroscience Trading Up 0.6 %

NYSE ANRO opened at $2.71 on Friday. Alto Neuroscience has a twelve month low of $2.58 and a twelve month high of $18.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The company’s 50-day simple moving average is $3.63 and its 200 day simple moving average is $6.15.

Wall Street Analyst Weigh In

Separately, William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Friday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.